Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine

Narita, Miwako; Kanda, Tatsuo; Abe, Takashi; Uchiyama, Takeo; Iwafuchi, Makoto; Zheng, Zhi; Liu, Aichun; Kaifu, Tsutomu; Kosugi, Shin‐ichi; Minagawa, Masahiro; Itoh, Kyogo; Takahashi, Masuhiro

doi:10.3892/ijo.2015.2846

Cited by 49 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) involved autologous DCs exposed to autologous tumor-derived RNA, 196 tumor-cell lysates, [197][198][199][200][201][202][203] autologous tumor stem cell lysates, 204 self-renewing and proliferating autologous tumor cells, 205 allogeneic cancer cell line lysates, [206][207][208] TAAs or TAA-derived peptides [209][210][211][212][213][214][215][216][217][218] or a combination thereof. 219 Most clinical studies based on the latter approach preferred melanoma-associated differentiation antigens including premelanosome protein (PMEL; also known as gp100), antigens belonging to the melanoma antigen gene (MAGE) family, tyrosinase (TYR) and Melan-A (MLANA; also known as MART1) (Fig.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

“…230 Regarding the distribution across different cancer types ( Fig. 1), patients harboring melanoma were most commonly enrolled in these trials, 186,196,198,205,213,221,223,227,[231][232][233][234] followed by patients with prostate cancer, 206,208,212,215 glioma or glioblastoma (GBM), 185,197,202,219 hepatocellular carcinoma, 204,211,220 non-small cell lung carcinoma (NSCLC), 207,214,230 renal cell carcinoma (RCC), 201,203 esophageal carcinoma, 216,226 and pancreatic ductal adenocarcinoma, 209,217 among others. Of note, only two trials included a wide range of advanced solid tumors refractory to previous treatments.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" (typically a combination of pro-inflammatory cytokines and Toll-like receptor agonists), followed by DC reintroduction into patients. DC vaccines have been documented to (re)activate tumor-specific T cells in both preclinical and clinical settings. There is considerable clinical interest in combining DC-based anticancer vaccines with T cell-targeting immunotherapies. This reflects the established capacity of DC-based vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into the tumor bed. In this Trial Watch, we survey the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics. We also highlight how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche for DC-based vaccines within the wide cancer immunotherapy landscape.

show abstract

Section: Completed Clinical Trialsmentioning

confidence: 99%

Section: Completed Clinical Trialsmentioning

confidence: 99%

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, it has been suggested that in clinical trials, in order to obtain enhanced vaccine efficiency, peptide-pulsed DCs are immunized mostly via s.c. or i.d. [52][53][54][55][56]. In further studies, a comparison on i.p.…”

Section: Discussionmentioning

confidence: 99%

Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides

et al. 2015

View full text Add to dashboard Cite

A B S T R A C TEukaryotic elongation factor-2 (eEF2) is overexpressed in many human cancers and is an attractive target for cancer immunotherapy. The eEF2 derived polypeptides have been shown to be able to induce cytotoxic T lymphocytes from healthy donor. Here, we demonstrate the evidence indicating that modification of a segment of peptides from wild type eEF2-derived immunogenic peptides is able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes (CTLs) against colon cancer cells. Using peptide-MHC binding algorithms, potential HLA-A2.1-restricted epitopes capable of inducing specific CD8 + CTLs were identified. By analyzing HLA-A2.1 affinity and immunogenicity, we further identified one novel immunogenic peptide, P739-747 (RLMEPIYLV), that elicited specific CTL responses in HLA-A2.1/K b transgenic mice and culture with peripheral blood lymphocytes from colon cancer patients. Furthermore, replacing certain amino acids (at positions 1, 3, 7) within the P739-747 sequence improved the immunogenicity against eEF2. Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. Thus, these results support that modified immunogenic analogs are promising candidates for peptide-based cancer vaccination and immunotherapy.

show abstract

“…Dendritic cells are one of the most potent antigen-presenting cells capable of ingesting apoptotic tumor cells and presenting tumor-associated antigens to T-cells (83). In pre-clinical studies, DC-based strategies showed strong effects against esophageal carcinoma cell lines (84), and were evaluated in clinical phase I/II studies to assess feasibility and efficacy (85).…”

Section: Esophageal Cancermentioning

confidence: 99%